Drug
Sitaxsentan and Sildenafil
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(100%)
Phase Distribution
Ph phase_3
2
100%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
2(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Terminated(2)
Detailed Status
Terminated2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 32 (100.0%)
Trials by Status
terminated2100%
Recent Activity
0 active trials
Showing 2 of 2
terminatedphase_3
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796510
terminatedphase_3
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
NCT00796666
Clinical Trials (2)
Showing 2 of 2 trials
NCT00796510Phase 3
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
NCT00796666Phase 3
Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2